Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $42,100.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 842 shares of the stock in a transaction that occurred on Friday, March 28th. The shares were sold at an average price of $50.00, for a total transaction of $42,100.00. Following the sale, the director now owns 278,945 shares in the company, valued at approximately $13,947,250. The trade was a 0.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Pro-Dex Stock Up 7.4 %

PDEX opened at $55.19 on Thursday. The stock has a market capitalization of $179.97 million, a price-to-earnings ratio of 27.46 and a beta of 0.40. The firm has a 50 day moving average price of $40.72 and a 200-day moving average price of $40.53. Pro-Dex, Inc. has a twelve month low of $16.84 and a twelve month high of $59.60. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.33.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. Equities research analysts forecast that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Analyst Ratings Changes

Separately, StockNews.com downgraded Pro-Dex from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in shares of Pro-Dex by 2.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after acquiring an additional 529 shares during the last quarter. FMR LLC raised its holdings in Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares during the period. Renaissance Technologies LLC lifted its position in Pro-Dex by 8.1% during the fourth quarter. Renaissance Technologies LLC now owns 14,740 shares of the medical instruments supplier’s stock valued at $689,000 after purchasing an additional 1,100 shares in the last quarter. Geode Capital Management LLC grew its holdings in Pro-Dex by 9.1% during the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after purchasing an additional 2,296 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in Pro-Dex during the fourth quarter valued at about $202,000. 15.28% of the stock is owned by hedge funds and other institutional investors.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.